HighGravityData
Companies / Biopharma / NBIX

Neurocrine Biosciences

NBIX · Biopharma sector group
Guidance from Neurocrine Biosciences’s last 8 earnings releases. Every value links to its sentence in the filing. See something wrong? Tell us.
Current guidance
16 items
Releases tracked
8
Latest release
Jul 30, 2026
Data checked
Jul 30, 2026
On this page:Latest changes·Current guidance·Your sector group·History

What changed in the Jul 30, 2026 release

Each item compared with the same item in the previous release (May 5, 2026). Values in quotation marks are the company’s words.

New — first stated in this releaseRaised / Lowered / Narrowed / Widened — changed from the prior releaseRevised — wording changed, direction not determinableChanged — value changed; the comparison couldn’t be parsed to a directionReiterated — restated unchangedNot restated — stated before, absent nowRaised and lowered describe the number, not whether the change is favorable.
ChangeMetricPeriodPreviousNowSource
NewINGREZZA® (valbenazine) 2026 Net Salesfor FY2026—“$2.825 to $2.875 Billion”Filing ↗
NewGAAP Amortization of Acquired Intangible Assetsfor FY2026—“$85 - $90”Filing ↗
NewGAAP R&Dfor FY2026—“$1,275 - $1,325”Filing ↗
NewGAAP SG&Afor FY2026—“$1,575 - $1,600”Filing ↗
RaisedINGREZZA Net Product Salesfor FY2026“$ 2,700 $ 2,800”“$2,825 - $2,875”Filing ↗
NewIPR&Dfor FY2026—“$23”Filing ↗
NewNon-GAAP R&Dfor FY2026—“$1,140 - $1,190”Filing ↗
NewNon-GAAP SG&Afor FY2026—“$1,325 - $1,350”Filing ↗
NewR&D development milestones expensefor FY2026—“approximately $25 million”Filing ↗
NewGAAP Amortization of Acquired Intangible AssetsNo period stated—“Not applicable”Filing ↗
NewGAAP R&DNo period stated—“$1,200 - $1,250”Filing ↗
NewGAAP SG&ANo period stated—“$1,375 - $1,400”Filing ↗
NewINGREZZA Net Product SalesNo period stated—“$2,700 - $2,800”Filing ↗
NewIPR&DNo period stated—“$20”Filing ↗
NewNon-GAAP R&DNo period stated—“$1,110 - $1,160”Filing ↗
NewNon-GAAP SG&ANo period stated—“$1,240 - $1,265”Filing ↗

Current guidance

Guidance for periods that have not yet ended, at its most recent value, grouped by horizon.

Current fiscal year
MetricCurrent valuePeriodMeasureFirst statedTimes statedSource
INGREZZA® (valbenazine) 2026 Net Sales“$2.825 to $2.875 Billion”for FY2026GAAP-tiedJul 30, 20261Filing ↗
INGREZZA® (valbenazine) Net Sales“$2.7 - $2.8 Billion”for FY2026GAAP-tiedMay 5, 20261Filing ↗
GAAP Amortization of Acquired Intangible Assets“$85 - $90”for FY2026GAAP-tiedJul 30, 20261Filing ↗
GAAP and Non-GAAP IPR&D“$20”for FY2026Company-definedFeb 11, 20262Filing ↗
GAAP R&D“$1,275 - $1,325”for FY2026Company-definedJul 30, 20261Filing ↗
GAAP R&D Expense“$ 1,200 $ 1,250”for FY2026Company-definedFeb 11, 20261Filing ↗
GAAP SG&A“$1,575 - $1,600”for FY2026Company-definedJul 30, 20261Filing ↗
GAAP SG&A Expense“$ 1,375 $ 1,400”for FY2026Company-definedFeb 11, 20261Filing ↗
INGREZZA Full Year Net Product Sales“$2.7 - $2.8 Billion”for FY2026Company-definedFeb 11, 20261Filing ↗
INGREZZA Net Product Sales“$2,825 - $2,875”for FY2026Company-definedFeb 11, 20262Filing ↗
IPR&D“$23”for FY2026Company-definedJul 30, 20261Filing ↗
Non-GAAP R&D“$1,140 - $1,190”for FY2026Company-definedJul 30, 20261Filing ↗
Non-GAAP R&D Expense“$ 1,110 $ 1,160”for FY2026Company-definedFeb 11, 20261Filing ↗
Non-GAAP SG&A“$1,325 - $1,350”for FY2026Company-definedJul 30, 20261Filing ↗
Non-GAAP SG&A Expense“$ 1,240 $ 1,265”for FY2026Company-definedFeb 11, 20261Filing ↗
R&D development milestones expense“approximately $25 million”for FY2026Company-definedJul 30, 20261Filing ↗
No period stated
MetricCurrent valuePeriodMeasureFirst statedTimes statedSource
Accelerated Share Repurchase Transaction“$300 million”—Declared actionOct 30, 20241Filing ↗
Remaining Share Repurchase Authorization“$332 million”—Declared actionJul 30, 20251Filing ↗
Share Repurchase Authorization“$300 Million”—Declared actionOct 30, 20241Filing ↗
Share repurchase program“up to $500 million”—Declared actionMay 5, 20251Filing ↗
Share Repurchase Program Authorization“up to $500 million”—Declared actionJul 30, 20251Filing ↗

How one item moved

INGREZZA Net Product Sales, for FY2026 — every statement across the year, each linked to its filing.

Feb 11, 2026
New
“$ 2,700 $ 2,800”
Filing ↗
Jul 30, 2026
Raised
“$2,825 - $2,875”
Filing ↗

How your Biopharma sector group guides

12 companies in Biopharma. What they guide on, and who reported this season.

Most-guided metric families
Revenue
11
Adjusted EPS
6
GAAP EPS
5
Tax rate
5
Buybacks
5
Gross margin
4
Capex
3
Dividends
3
This season’s releases
BioMarin PharmaceuticalAug 6, 202619 changes
Halozyme TherapeuticsAug 6, 20266 changes
Eli LillyAug 5, 20265 changes
AmgenAug 4, 20265 changes
Gilead SciencesAug 4, 202615 changes
ModernaJul 31, 20268 changes
Neurocrine BiosciencesJul 30, 202616 changes
Regeneron PharmaceuticalsJul 30, 202622 changes
Get this for your own peer set — Peer Guidance Briefing, $3,000.

Full history

Every metric, every release, eight quarters — the complete record as one table.

MetricFY2026FY2025FY2024No period
INGREZZA® (valbenazine) 2026 Net Sales2 statements———
Accelerated Share Repurchase Transaction———1 statement
GAAP Amortization of Acquired Intangible Assets1 statement——1 statement
GAAP and Non-GAAP IPR&D2 statements———
GAAP R&D1 statement——1 statement
The full record for Neurocrine Biosciences and its Biopharma peers, delivered as a Peer Guidance Briefing — PDF and Excel, every value linked to its filing.

Filings

The 8 earnings releases this page is built from.

FiledFiscal periodAccessionGuidance items
Jul 30, 2026FY2026 Q20000914475-26-00003516Open filing ↗
May 5, 2026FY2026 Q10000914475-26-0000252Open filing ↗
Feb 11, 2026FY2025 Q40000914475-26-0000067Open filing ↗
Oct 28, 2025FY2025 Q30000914475-25-0001800Open filing ↗
Jul 30, 2025FY2025 Q20000914475-25-0001573Open filing ↗
May 5, 2025FY2025 Q10000914475-25-0000992Open filing ↗
Feb 6, 2025FY2024 Q40000914475-25-0000341Open filing ↗
Oct 30, 2024FY2024 Q30000914475-24-0002104Open filing ↗
Values in quotation marks are the company’s words; the classification and filing links are HighGravityData’s. HighGravityData does not score or rank companies or give investment advice.
Report an error